SE465950B - Kombination av ett aggregat partikelformat, kristallint eller frystorkat laekemedel med en pseudoplastisk gel foer beredning av ett injicerbart preparat samt foerfarande foer dess framstaellning - Google Patents

Kombination av ett aggregat partikelformat, kristallint eller frystorkat laekemedel med en pseudoplastisk gel foer beredning av ett injicerbart preparat samt foerfarande foer dess framstaellning

Info

Publication number
SE465950B
SE465950B SE8903503A SE8903503A SE465950B SE 465950 B SE465950 B SE 465950B SE 8903503 A SE8903503 A SE 8903503A SE 8903503 A SE8903503 A SE 8903503A SE 465950 B SE465950 B SE 465950B
Authority
SE
Sweden
Prior art keywords
drug
combination
pseudoplastic gel
preparation
pseudoplastic
Prior art date
Application number
SE8903503A
Other languages
English (en)
Swedish (sv)
Other versions
SE8903503L (sv
SE8903503D0 (sv
Inventor
T Fjellstroem
Original Assignee
Medinvent Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinvent Sa filed Critical Medinvent Sa
Priority to SE8903503A priority Critical patent/SE465950B/sv
Publication of SE8903503D0 publication Critical patent/SE8903503D0/xx
Priority to CA002067228A priority patent/CA2067228C/en
Priority to AU66237/90A priority patent/AU632634B2/en
Priority to PCT/SE1990/000683 priority patent/WO1991005544A1/en
Priority to EP90916175A priority patent/EP0497846B1/de
Priority to AT90916175T priority patent/ATE143257T1/de
Priority to JP2514918A priority patent/JP3017801B2/ja
Priority to DE69028710T priority patent/DE69028710T2/de
Priority to DE1990916175 priority patent/DE497846T1/de
Publication of SE8903503L publication Critical patent/SE8903503L/
Publication of SE465950B publication Critical patent/SE465950B/sv
Priority to US08/344,707 priority patent/US5614221A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
SE8903503A 1989-10-23 1989-10-23 Kombination av ett aggregat partikelformat, kristallint eller frystorkat laekemedel med en pseudoplastisk gel foer beredning av ett injicerbart preparat samt foerfarande foer dess framstaellning SE465950B (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE8903503A SE465950B (sv) 1989-10-23 1989-10-23 Kombination av ett aggregat partikelformat, kristallint eller frystorkat laekemedel med en pseudoplastisk gel foer beredning av ett injicerbart preparat samt foerfarande foer dess framstaellning
DE1990916175 DE497846T1 (de) 1989-10-23 1990-10-22 Arzneiabgabesystem, verfahren zu dessen herstellung sowie dessen verwendung.
EP90916175A EP0497846B1 (de) 1989-10-23 1990-10-22 Arzneiabgabesystem, verfahren zu dessen herstellung sowie dessen verwendung
AU66237/90A AU632634B2 (en) 1989-10-23 1990-10-22 Drug delivery system, method for preparing the same, and use thereof
PCT/SE1990/000683 WO1991005544A1 (en) 1989-10-23 1990-10-22 Drug delivery system, method for preparing the same, and use thereof
CA002067228A CA2067228C (en) 1989-10-23 1990-10-22 Drug delivery system, method for preparing the same and use thereof
AT90916175T ATE143257T1 (de) 1989-10-23 1990-10-22 Arzneiabgabesystem, verfahren zu dessen herstellung sowie dessen verwendung
JP2514918A JP3017801B2 (ja) 1989-10-23 1990-10-22 薬剤デリバリーシステム、その製造方法および使用
DE69028710T DE69028710T2 (de) 1989-10-23 1990-10-22 Arzneiabgabesystem, verfahren zu dessen herstellung sowie dessen verwendung
US08/344,707 US5614221A (en) 1989-10-23 1994-11-21 Method of preparing a drug delivery system comprising a drug and a gel using a syringe

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8903503A SE465950B (sv) 1989-10-23 1989-10-23 Kombination av ett aggregat partikelformat, kristallint eller frystorkat laekemedel med en pseudoplastisk gel foer beredning av ett injicerbart preparat samt foerfarande foer dess framstaellning

Publications (3)

Publication Number Publication Date
SE8903503D0 SE8903503D0 (sv) 1989-10-23
SE8903503L SE8903503L (sv) 1991-04-24
SE465950B true SE465950B (sv) 1991-11-25

Family

ID=20377242

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8903503A SE465950B (sv) 1989-10-23 1989-10-23 Kombination av ett aggregat partikelformat, kristallint eller frystorkat laekemedel med en pseudoplastisk gel foer beredning av ett injicerbart preparat samt foerfarande foer dess framstaellning

Country Status (9)

Country Link
US (1) US5614221A (de)
EP (1) EP0497846B1 (de)
JP (1) JP3017801B2 (de)
AT (1) ATE143257T1 (de)
AU (1) AU632634B2 (de)
CA (1) CA2067228C (de)
DE (1) DE69028710T2 (de)
SE (1) SE465950B (de)
WO (1) WO1991005544A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2995090B2 (ja) * 1993-03-19 1999-12-27 キユー・メド・アクチエボラーグ 組織増大のための組成物および方法
US5716631A (en) * 1995-09-29 1998-02-10 Rdn Therapeutics Inc. Long acting narcotic analgesics and antagonists
AU713276B2 (en) * 1996-05-23 1999-11-25 Samyang Corporation Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
AU739469B2 (en) * 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
PT1397155E (pt) 2001-06-21 2015-12-07 Genentech Inc Formulação de libertação sustentada
CN1671400A (zh) * 2002-07-03 2005-09-21 派瑞克科学公司 透明质酸组合物以及使用方法
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
FR2850282B1 (fr) 2003-01-27 2007-04-06 Jerome Asius Implant injectable a base de ceramique pour le comblement de rides, depressions cutanees et cicatrices, et sa preparation
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
US8968786B2 (en) 2007-06-22 2015-03-03 Board Of Regents, The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
EP3458084B1 (de) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663685A (en) * 1968-04-01 1972-05-16 Minnesota Mining & Mfg Biodegradable radioactive particles
US4169804A (en) * 1976-08-19 1979-10-02 Minnesota Mining And Manufacturing Company Magnetically responsive composite microparticle
US4474752A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
DE3484584D1 (de) * 1983-10-14 1991-06-20 Sumitomo Pharma Injektionen mit verzoegerter abgabe.
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
IT1186766B (it) * 1985-11-08 1987-12-16 Sclavo Spa Metodo per la preparazione di immunoglobuline per uso endovenoso
DE3684887D1 (de) * 1985-11-29 1992-05-21 Biomatrix Inc Arzneistoffabgabesysteme auf basis von hyaluronan, dessen derivaten und salzen sowie verfahren zu deren herstellung.
JPS63624A (ja) * 1986-06-19 1988-01-05 Nec Corp 正規乱数発生方法
DE3626868A1 (de) * 1986-08-08 1988-02-11 Bayer Ag Parenterale loesung

Also Published As

Publication number Publication date
JPH05503921A (ja) 1993-06-24
US5614221A (en) 1997-03-25
SE8903503L (sv) 1991-04-24
DE69028710D1 (de) 1996-10-31
AU6623790A (en) 1991-05-16
AU632634B2 (en) 1993-01-07
SE8903503D0 (sv) 1989-10-23
JP3017801B2 (ja) 2000-03-13
DE69028710T2 (de) 1997-04-17
CA2067228C (en) 2002-01-08
CA2067228A1 (en) 1991-04-24
EP0497846B1 (de) 1996-09-25
ATE143257T1 (de) 1996-10-15
EP0497846A1 (de) 1992-08-12
WO1991005544A1 (en) 1991-05-02

Similar Documents

Publication Publication Date Title
SE465950B (sv) Kombination av ett aggregat partikelformat, kristallint eller frystorkat laekemedel med en pseudoplastisk gel foer beredning av ett injicerbart preparat samt foerfarande foer dess framstaellning
DE69721265T2 (de) Hydrolysierbare hydrogele zur gesteuerten freisetzung
DK174804B1 (da) Fremgangsmåde til fremstilling af selvdispergerbare blokcopolymerer, copolymerlægemiddelpulver, fremgangsmåde til fremstilling heraf samt fremgangsmåder til fremstilling af frosne, stabile, vandige dispersioner af copolymer og lægemiddel
CN1234416C (zh) 持续释放疏水药物的组合物及其制备方法
US4853226A (en) Sustained-release particulate preparation and process for preparing the same
CN1527698B (zh) 控释可生物降解的凝胶基质
CN100500211C (zh) 用凝血酶派生的肽的治疗方法
CN101137349B (zh) 基于pegt/pbt嵌段共聚物的控制释放组合物
HU228462B1 (en) Implant for subcutaneous or intradermal injection
MXPA03002552A (es) Formulaciones de administracion polimerica de leuprolida con eficacia mejorada.
CN109627463B (zh) 水凝胶与蛋白质药物
EA018203B1 (ru) Композиция пролонгированного высвобождения, содержащая памоат пасиреотида в микрочастицах с полимерной матрицей, способ получения микрочастиц и способ лечения
JPS62230729A (ja) Ｃｓｆ徐放性製剤
CN103432570B (zh) 一种胸腺法新缓释微球及其制备方法
CN111358934B (zh) 一种醋酸亮丙瑞林长效药物制剂组合及其使用方法
CN101618208B (zh) 含微粉化重组人血管内皮抑制素缓释微球的制备方法
CN100372567C (zh) 促进心脏组织修复的凝血酶衍生肽
CN101568351B (zh) 控制释放的组合物和方法
JP2837675B2 (ja) 徐放性微粒製剤
JPS60126217A (ja) 長期徐放性製剤
CN1526372A (zh) 一种抑制突释效应的长效注射剂
CN103222959A (zh) 一种白介素-2长效缓释微球及其制备方法和应用
CN104721806B (zh) Pmx‑53明胶复合微粒及其制备方法
CN114073758B (zh) 化合物Isaridin E或其药用盐在制备抗血栓药物中的应用
CN101954065A (zh) 注射用重组人血管内皮抑制素纳米粒组合物及制备方法

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8903503-4

Format of ref document f/p: F

NUG Patent has lapsed